An injection given just twice a year could herald a breakthrough in protecting the population that has the highest infection rates.
Tag: Gilead Sciences Inc
F.D.A. Approves Remdesivir for Patients Not Hospitalized
The treatment must be given via intravenous infusion over three consecutive days, generally at a hospital or clinic.
Shot to Prevent H.I.V. Works Better Than Daily Pill in Women
Researchers ended a clinical trial of the drug early because the results were so convincing. The more effective drug would be given in six injections a year instead of as 365 daily pills.
Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial
Critics said the study, sponsored by the W.H.O., was too poorly conducted to be definitive.
Remdesivir Coronavirus Trial: Federal Scientists Finally Publish Data
A clinical trial led to the authorization of the only drug shown to work in Covid-19 patients. But until now, few experts had seen the numbers.
Moderna Vaccine Trial: How Upbeat Coronavirus News Fueled a Stock Surge
The desperate hunt for treatments and vaccines has changed how researchers, regulators, drug companies like Moderna, investors and journalists do their jobs.
How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected
The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on the coronavirus.
Remdesivir Shows Modest Benefits in Coronavirus Trial
Hope soared nonetheless. The F.D.A. is likely to issue an emergency approval, a senior official said.
At the Center of a Storm: The Search for a Proven Coronavirus Treatment
Taking an experimental drug can be worse than taking nothing at all, warns Dr. Andre Kalil: “You are treating emotion.”
Coronavirus Patients in Limbo as Gilead Suspends Emergency Drug Access
The company says it will switch to a broader approach for its experimental drug, remdesivir. But it was overwhelmed by demand for a potential treatment promoted by President Trump.